An Extension Study of Ublituximab in Participants With Relapsing Multiple Sclerosis
Public ClinicalTrials.gov record NCT04130997. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Open Label Extension Study of Ublituximab in Subjects With Relapsing Multiple Sclerosis
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to evaluate long-term safety and efficacy of ublituximab therapy in participants with relapsing multiple sclerosis (RMS).
Study identification
- NCT ID
- NCT04130997
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 1,100 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 18, 2019 (Actual)
- Primary completion
- May 31, 2032 (Estimated)
- Completion
- May 31, 2032 (Estimated)
- Last update posted
- Sep 23, 2026
2019 – 2032
United States locations
- U.S. sites
- 19
- U.S. states
- 14
- U.S. cities
- 19
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| TG Therapeutics Investigational Trial Site | Pasadena | California | 91105 | — |
| TG Therapeutics Investigational Trial Site | Denver | Colorado | 80045 | — |
| TG Therapeutics Investigational Trial Site | Miami | Florida | 33136 | — |
| TG Therapeutics Investigational Trial Site | Tampa | Florida | 33612 | — |
| TG Therapeutics Investigational Trial Site | Northbrook | Illinois | 60062 | — |
| TG Therapeutics Investigational Trial Site | Kansas City | Kansas | 66160 | — |
| TG Therapeutics Investigational Trial Site | Detroit | Michigan | 48201 | — |
| TG Therapeutics Investigational Trial Site | Las Vegas | Nevada | 89106 | — |
| TG Therapeutics Investigational Trial Site | Teaneck | New Jersey | 07666 | — |
| TG Therapeutics Investigational Trial Site | Albuquerque | New Mexico | 87131 | — |
| TG Therapeutics Investigational Trial Site | Amherst | New York | 14266 | — |
| TG Therapeutics Investigational Trial Site | Columbus | Ohio | 43214 | — |
| TG Therapeutics Investigational Trial Site | Westerville | Ohio | 43081 | — |
| TG Therapeutics Investigational Trial Site | Knoxville | Tennessee | 37922 | — |
| TG Therapeutics Investigational Trial Site | Dallas | Texas | 75246 | — |
| TG Therapeutics Investigational Trial Site | Frisco | Texas | 75034 | — |
| TG Therapeutics Investigational Trial Site | Round Rock | Texas | 78681 | — |
| TG Therapeutics Investigational Trial Site | San Antonio | Texas | 78258 | — |
| TG Therapeutics Investigational Trial Site | Seattle | Washington | 98109 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 67 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04130997, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 23, 2026 · Synced Oct 25, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT04130997 live on ClinicalTrials.gov.